Injectable Buprenorphine: New Factsheets from CTN PNW Node

Video cover

Buprenorphine is one of three medications (methadone and naltrexone being the other two) approved for use to treat opioid use disorder. It is available as a film or tablet, and more recently as two long-acting extended-release injectables. Sublocade™ was first to be approved by the FDA in November 2017. More recently, in May 2023, Brixadi™ received approval. In January 2024 it was added to the WA state Medicaid formulary.

Fewer clinicians have experience using Brixadi™ than Sublocade™. The CTN Pacific Northwest Node recently developed a set of videos intended to aid prescribers in their conversations with patients interested in these buprenorphine options, and have now added two new factsheets too:

Find the complete set of resources here!